Eltrombopag for Chemotherapy-induced Thrombocytopenia
Trial Parameters
Brief Summary
To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years old, male or female; * Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT); Ineffective after repeated treatment with rhTPO or IL-11； * Stop radiotherapy or chemotherapy for more than 1 month; * Platelet counts \<30 ×10\^9/L, and bleeding tendency; * Estimated survival period ≥ 6 months； * People who are willing to sign the informed consent voluntarily and follow the research program. * Liver and kidney function\<1.5×upper limit of normal, qualified for physical examination； * Subject is practicing an acceptable method of contraception. Women of childbearing potential must have a negative serum pregnancy test in the whole study; Exclusion Criteria: * Those with uncontrollable primary diseases of important organs, such as extensive metastasis of malignant tumors, liver failure, heart failure, kidney failure and other diseases； * Patients with poor compliance; * Positive serology for HIV, hepatitis B virus (HBV), hepatiti